Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Fiche du document
- doi: 10.1371/journal.pmed.1003421
- issn: 1549-1277
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pmed.1003421
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33170863
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1549-1676
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7D241934CD716
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Upper limb Limb, Upper Upper extremities Extremity, Upper Pectoral limbs Limb, Pectoral Thoracic limbs Extremities, Upper Upper limbs Limb, Thoracic Arms (Anatomy) Thoracic limb Upper extremity Pectoral limbCiter ce document
D. Sculier et al., « Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. », Serveur académique Lausannois, ID : 10.1371/journal.pmed.1003421
Métriques
Partage / Export
Résumé
Dolutegravir (DTG)-based dual therapy is becoming a new paradigm for both the initiation and maintenance of HIV treatment. The SIMPL'HIV study investigated the outcomes of virologically suppressed patients on standard combination antiretroviral therapy (cART) switching to DTG + emtricitabine (FTC). We present the 48-week efficacy and safety data on DTG + FTC versus cART. SIMPL'HIV was a multicenter, open-label, non-inferiority randomized trial with a factorial design among treatment-experienced people with HIV in Switzerland. Participants were enrolled between 12 May 2017 and 30 May 2018. Patients virologically suppressed for at least 24 weeks on standard cART were randomized 1:1 to switching to DTG + FTC or to continuing cART, and 1:1 to simplified patient-centered monitoring versus standard monitoring. The primary endpoint was the proportion of patients virologically suppressed with